Elsevier

European Journal of Cancer

Volume 32, Issue 9, August 1996, Pages 1464-1476
European Journal of Cancer

Special paper
A realistic clinical perspective of tamoxifen and endometrial carcinogenesis

https://doi.org/10.1016/0959-8049(96)00184-0Get rights and content

Abstract

Tamoxifen has been the endocrine treatment of choice for all stages of breast cancer for nearly a decade. Millions of women are currently receiving tamoxifen worldwide, while large-scale randomised trials have been launched aiming to investigate the drug's merit as a preventive agent. However, there are now concerns about tamoxifen's potential carcinogenicity. The goal of this review is to address these concerns, re-evaluate the available data from laboratory biological models and those from clinical reports and put the whole issue into perspective. Our focus is the association between tamoxifen and the increased frequency of endometrial tumours, while key issues, such as the role of duration of tamoxifen therapy, are also addressed. Finally, we discuss the various monitoring strategies for early detection of endometrial lesions and pertinent problems most likely to be encountered by clinicians taking care of patients who are receiving tamoxifen.

References (75)

  • VC Jordan

    What if tamoxifen (ICI 46,474) had been found to produce liver tumors in 1973?

    Ann Oncol

    (1995)
  • RP Kedar et al.

    Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial

    Lancet

    (1994)
  • LE Gibson et al.

    Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of tamoxifen users and nonusers

    Cancer J Sci Am

    (1996)
  • P Neven

    Endometrial changes in patients on tamoxifen

    Lancet

    (1995)
  • K Pritchard et al.

    Adjuvant tamoxifen in postmenopausal women with axillary node positive breast cancer. An update

  • Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths in 75000 women

    Lancet

    (1992)

    Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31000 recurrences and 24000 deaths in 75000 women

    Lancet

    (1992)
  • BA Furr et al.

    The pharmacology and clinical uses of tamoxifen

    Pharmacol Ther

    (1984)
  • RR Love et al.

    Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

    N Engl J Med

    (1992)
  • B Kristensen et al.

    Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study

    J Clin Oncol

    (1994)
  • MM Bilimoria et al.

    Should adjuvant tamoxifen therapy be stopped at 5 years?

    Cancer J Sci Am

    (1996)
  • F Boccardo et al.

    Endocrine effects of tamoxifen in postmenopausal breast cancer patients

    Tumori

    (1984)
  • CC McDonald et al.

    Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial

  • P Neven et al.

    Tamoxifen and the uterus and endometrium

    Lancet

    (1989)
  • RR Love

    Tamoxifen in healthy premenopausal and postmenopausal women: different risks and benefits

    J Natl Cancer Inst

    (1994)
  • P Neven et al.

    Tamoxifen and the uterus

    Br J Med

    (1994)
  • B Fisher et al.

    New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent

    J Natl Cancer Inst

    (1991)
  • TJ Powles et al.

    The Royal Marsden Hospital pilot tamoxifen chemoprevention trial

    Breast Cancer Res Treat

    (1994)
  • C Vanchieri

    Breast cancer study initiated in Italy

    J Natl Cancer Inst

    (1992)
  • MA Killackey et al.

    Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens

    Cancer Treat Rep

    (1985)
  • VJ Assikis et al.

    Gynecologic effects of tamoxifen and the association with endometrial carcinoma

    Int J Gynecol Obstet

    (1995)
  • JD Yager et al.

    Effects of ethinyl estradiol and tamoxifen on liver DNA turnover and new synthesis and appearance of gamma glutamyl transpeptidase-positive foci in female rats

    Carcinogenesis

    (1986)
  • P Hirsimaki et al.

    Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens

    Arch Toxicol

    (1993)
  • GM Williams et al.

    The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat

    Carcinogenesis

    (1993)
  • P Greaves et al.

    Two-year carcinogenicity study of tamoxifen in Alderley Park Wistar-derived rats

    Cancer Res

    (1993)
  • P Carthew et al.

    DNA damage as assessed by 32P-postlabelling in three rat strains exposed to dietary tamoxifen: the relationship between cell proliferation and liver tumor formation

    Carcinogenesis

    (1995)
  • INH White et al.

    Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells

    Carcinogenesis

    (1992)
  • X Han et al.

    Induction of covalent DNA adducts in rodents by tamoxifen

    Cancer Res

    (1992)
  • Cited by (119)

    • Ovarian cysts in tamoxifen-treated women with breast cancer

      2005, European Journal of Obstetrics and Gynecology and Reproductive Biology
    View all citing articles on Scopus
    View full text